| Severe Combined Immunodeficiency
Flebogamma DIF 5% vs Xembify
Side-by-side clinical, coverage, and cost comparison for severe combined immunodeficiency.Deep comparison between: Flebogamma vs Xembify with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsXembify has a higher rate of injection site reactions vs Flebogamma based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Xembify but not Flebogamma, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Flebogamma
Xembify
At A Glance
IV infusion
Every 3-4 weeks
Immune globulin (IGIV)
SC injection
Daily to every 2 weeks
Immune globulin replacement
Indications
- Common Variable Immunodeficiency
- X-linked agammaglobulinemia
- Severe Combined Immunodeficiency
- Wiskott-Aldrich Syndrome
- Primary immune deficiency disorder
- Congenital agammaglobulinemia
- Common Variable Immunodeficiency
- X-linked agammaglobulinemia
- Wiskott-Aldrich Syndrome
- Severe Combined Immunodeficiency
Dosing
Common Variable Immunodeficiency, X-linked agammaglobulinemia, Severe Combined Immunodeficiency, Wiskott-Aldrich Syndrome 300-600 mg per kg body weight IV every 3-4 weeks; initial infusion rate 0.01 mL/kg/min (0.5 mg/kg/min), increased to maximum 0.10 mL/kg/min (5 mg/kg/min) if tolerated.
Primary immune deficiency disorder, Congenital agammaglobulinemia, Common Variable Immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich Syndrome, Severe Combined Immunodeficiency SC infusion only; treatment-naive: 150 mg/kg/day loading dose for 5 consecutive days, then 150 mg/kg/week maintenance starting Day 8; switching from IVIG: begin 1 week after last IVIG, initial weekly dose (g) = prior IVIG dose (g) x 1.37 / number of weeks between IVIG doses; switching from IGSC: administer same weekly dose (g) as prior IGSC; doses may be adjusted for frequent (2-7 times/week) or biweekly administration.
Contraindications
- History of anaphylactic or severe systemic hypersensitivity reactions to human immune globulin
- IgA-deficient patients with antibodies to IgA and a history of hypersensitivity
- Previous anaphylactic or severe systemic reaction to human immune globulin
- IgA deficiency with antibodies against IgA and history of hypersensitivity to human immune globulin treatment
Adverse Reactions
Most common, adults (>=5%) Headache, pyrexia, pain, injection site reactions, diarrhea, rigors, urticaria, infusion site inflammation
Most common, pediatrics (>=5%) Headache, pyrexia, hypotension, tachycardia, diastolic hypotension, nausea, abdominal pain, diarrhea, pain, vomiting
Postmarketing Hypersensitivity/anaphylaxis, acute renal dysfunction/failure, ARDS, TRALI, cardiac arrest, thromboembolism, coma, seizures, aseptic meningitis syndrome, Stevens-Johnson Syndrome, pancytopenia, hemolysis
Most common (>=5%) Infusion site erythema, infusion site pain, infusion site swelling, infusion site bruising, infusion site nodule, infusion site pruritus, infusion site induration, infusion site scab, infusion site edema, cough, diarrhea
Postmarketing Anaphylactic reaction, hypersensitivity, aseptic meningitis, dizziness, paresthesia, tachycardia, hypotension, dyspnea, chest discomfort, injection site reactions, chills, fatigue, pain, tremor, laryngospasm
Pharmacology
Flebogamma 5% DIF is an intravenous immune globulin (IGIV) that provides replacement therapy for primary immunodeficiency by supplying a broad spectrum of opsonizing and neutralizing IgG antibodies against a wide variety of bacterial and viral agents.
XEMBIFY supplies a broad spectrum of opsonizing and neutralizing IgG antibodies against bacterial, viral, parasitic, and mycoplasmal agents and their toxins, and contains antibodies capable of interacting with and altering the activity of immune system cells, though the full mechanism is not completely understood.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Flebogamma
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
Xembify
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (0/12)
UnitedHealthcare
Flebogamma
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Xembify
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Flebogamma
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Xembify
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Flebogamma.
Cost estimate not availableAccessia Health: Primary Immune Deficiency - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
FlebogammaView full Flebogamma profile
XembifyView full Xembify profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.